Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma

Treatment with programmed death-1 (PD-1) blocking antibodies results in high overall response rates in refractory and relapsed classical Hodgkin lymphoma (cHL) patients, indicating that PD-1/PD-1 ligand interactions are integral to progression of this disease. Given the genetically driven increased...

Descripción completa

Detalles Bibliográficos
Autores principales: Jalali, Shahrzad, Price-Troska, Tammy, Bothun, Cole, Villasboas, Jose, Kim, Hyo-Jin, Yang, Zhi-Zhang, Novak, Anne J., Dong, Haidong, Ansell, Stephen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381098/
https://www.ncbi.nlm.nih.gov/pubmed/30783096
http://dx.doi.org/10.1038/s41408-019-0185-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381098/
https://www.ncbi.nlm.nih.gov/pubmed/30783096
http://dx.doi.org/10.1038/s41408-019-0185-9

Ejemplares similares